Remission-Survival Discordance With Blinatumomab in Relapsed/Refractory Acute Lymphoblastic Leukemia: A Propensity-Matched Real-World Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-471; "In this propensity-matched real-world analysis, blinatumomab was associated with significantly higher remission rates but no statistically significant improvement in 12-month OS compared with salvage chemotherapy. This remission-survival discordance may reflect differences in treatment sequencing, subsequent transplantation, and unmeasured disease biology not captured in structured real-world datasets. These findings support the clinical activity of blinatumomab in routine practice while highlighting the importance of treatment context when interpreting survival outcomes in adults with R/R ALL."
Clinical • Discordant • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Malik Abubakar MD 1; Sindhu Chadalawada MD 2; Preetham Ezhilarasu MD 2; Alsu Ramazanova MD 1; Abyot Teshome MD 1; Tanzina Nowrin MD 1; Balqees Ara MD 1; Abhishek Kumar MD 2
|